Recommended Global Microbiology Conferences
Nosocomial Infections 2018
Nosocomial infections 2018
Conference Series LLC Ltd invites all the participants from all over the world to attend “2nd International Congress on Nosocomial and Healthcare associated Infections” scheduled during October 15-16, 2018 in Las Vegas, USA. Nosocomial Infections 2018 brings together the global leaders in Nosocomial Infections and Healthcare to present their research at this exclusive scientific program. The Nosocomial Infections conference hosting presentations from editors of prominent refereed journals, renowned and active investigators and decision makers in the field of infectious diseases, immunology, microbiology, infection prevention and infection control. Nosocomial Infections 2018 Organizing Committee also invites young investigators at every career stage to submit abstracts reporting their latest scientific findings in oral and poster sessions.
Nosocomial Infections (NIs) or Hospital-Acquired Infections (HAIs) are a major complication for professionals of health care to tackle. Every day, NIs results in longer hospital stays, long-term disability, and increasing the resistance of microorganisms to antimicrobials, additional massive costs to health care systems, high costs for patients and their families, and unnecessary deaths. Prevention and infection control is needed to prevent transmission of infectious diseases in all health care settings. Infection prevention and control demands a basic understanding of the epidemiology of diseases, risk factors that increase patient susceptibility to infection, and the practices, procedures and treatments that may result in infections. The risk of acquiring Nosocomial infections is related to the mode of transmission of the infectious agent (e.g. Clostridium difficile -CDI, Surgical Site Infections-SSI, Carbapenem-resistant Enterobacteriacae -CRE, Methicillin-resistant Staphylococcus aureus-MRSA, etc.) and the type of patient-care activity or procedure being performed and the underlying patient’s host defences.
The conference attains significance when we look at the Data and Statistics of Nosocomial Infections (NIs) or Hospital Acquired Infections (HAIs) by Centre for Disease Control and Prevention (CDC) .In 2014, the results of a project known as HAI Prevalence Survey were published. The survey describes the burden of nosocomial infections in US hospitals, and reported that in 2011 there were about 722,000 NIs in US acute care hospitals. In addition, approximately 75,000 patients with NIs died during their hospitalization. More than half of all hospital infections took place outside the intensive care unit.
Who should attend?
- Infectious Disease Consultants
- Medical Laboratory Supervisors
- Internal Medicine Consultants
- Infection Control Personnel
- Health Care Professionals
- Laboratory Technologists
- Infection Control Nurses
- Patient Safety Managers
- Medical Technologists
- Clinical Scientists
Why to attend?
With members from around the world focused on learning about global trends on emerging infectious diseases and its advances in therapeutic and diagnostic market, this is your best opportunity to reach the largest assemblage of participants from the Infectious diseases community. This particular conference conduct presentations, distributes information, conducts meetings with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2 day event. World renowned speakers, the most recent therapeutic and diagnostic techniques, developments, and the Novel technologies and therapeutic measures for Nosocomial infection and Healthcare are hallmarks of this conference.
- Directors, Board Members, Presidents, Vice Presidents, Deans and Head of the Departments
- Infectious Diseases Associations and related fields of Investigation
- Infectious Diseases Researchers, Scientists, Faculties, Students
- Laboratory Technicians and Diagnostic Companies
- Drug Manufacturing Companies and Industries
- Medical Devices Manufacturing Companies
- Pharmaceutical Companies and Industries
- Health care organizations and societies
- Medical Colleges
For Scientific Sessions please go through the link: http://nosocomialinfections.conferenceseries.com/call-for-abstracts.php
For Abstract Submission please go through the link: http://nosocomialinfections.conferenceseries.com/abstract-submission.php
Sessions & Tracks
Track 1: Nosocomial Infections
A nosocomial infection is contracted because of an infection or toxin that exists in a certain location, such as a hospital. Nosocomial Infections are one of the major complications for health care professionals to tackle. Every day they results in prolonged hospital stays, long-term disability, and increased resistance of microbes to antimicrobials, additional costs for healthcare systems, high costs for patients and their family, and unnecessary deaths
- Infections in dialysis patients
- Infections in obstetrics and gynaecology patients
- Infections in oncology patients
- Infections in immunocompromised hosts
- Infections in patients with renal, liver, CNS diseases
- Infections in transplant patients
- Infections in intensive care units
- Factors leading to emergence of nosocomial Infection
- Infections in tracheostomy patients
Track 2: Healthcare-associated Infections
Healthcare-associated infections (HAIs) refer to infections associated with the delivery of healthcare in hospitals, long-term care facilities, ambulatory settings, home care and other settings. These unanticipated infections that develop during the course of medical or surgical treatment may result in significant patient illnesses and deaths (morbidity and mortality); prolong the duration of hospital stays; and necessitate additional diagnostic and therapeutic interventions, which generate added costs.
- Catheter-associated urinary tract infection (CAUTI)
- Central line-associated bloodstream infection (CLABSI)
- Ventilator-associated events
- Chronic Obstructive Pulmonary Disease
Track 3: Surgical Site Infection (SSI)
A surgical site infection is an infection that occurs after surgery in the part of the body where the surgery took place. Surgical site infections can sometimes be superficial infections involving the skin only. Other surgical site infections are more serious and can involve tissues under the skin, organs, or implanted material. The causative pathogens depend on the type of surgery; the most commonly isolated organisms are Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus spp. and Escherichia coli.
- surgical wound infections
- Wound dressings
- Clinical care standards in surgery
- Advances in invasive surgery to prevent infections
Track 4: Urinary Tract Infections
A urinary tract infection (UTI) is an infection involving any part of the urinary system, including urethra, bladder, ureters, and kidney. UTIs are the most common type of healthcare-associated infection. Among UTIs acquired in the hospital, approximately 75% are associated with a urinary catheter, which is a tube inserted into the bladder through the urethra to drain urine.
- Catheter-associated Urinary Tract Infections (CAUTI)
- Health Care–Acquired Urinary Tract Infection
- Nosocomial urinary tract infection
- Infection rate of Indwelling urethral catheter
Track 5: Ventilator-associated pneumonia
Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are important causes of morbidity and mortality, with mortality rates approaching 62%. HAP and VAP are the second most common cause of nosocomial infection overall, but are the most common cause documented in the intensive care unit setting. In addition, HAP and VAP produce the highest mortality associated with nosocomial infection.
- Mycoplasma Pneumonia
- Bacterial Pneumonia
- Viral Pneumonia
- Community-acquired pneumonia
- Respiratory disorders and Infections
Track 6: Blood Stream Infections/Bacteraemia
Blood Infections or Bacteraemia or Sepsis occurs when a bacterial infection occur somewhere else in the body such as in the lungs or skin which enters the blood stream. This is dangerous because bacteria and their toxins can be transported through the bloodstream to the entire body.
- Central Line-associated Bloodstream Infection
- Hospital-Acquired Bloodstream Infections
- Nosocomial bloodstream infections
- Prevention of Blood Stream Infections
- Diabetic foot ulcer
Track 7: Infection Prevention and Control
Effective infection prevention and control is central of providing high quality health care for patients and a safe working environment for those that work in healthcare settings. It is important to minimize the risk of spread of infection to patients and staff in hospital by implementing good infection control program.
- Decontamination and sterilization
- Cleaning of the hospital environment
- Disinfection of patient equipment
- Operating room environment and Operating room staff
Track 8: Device-Associated Infections and Microbial Biofilms
Medical devices are responsible for a large portion of nosocomial infections, particularly in critically ill patients. Device associated infections can cause major medical and economic sequelae. Bacterial colonization and biofilm formation around the indwelling device can be a prelude to both infection and malfunction of the device.
- Resistance and Tolerance of Biofilms to Antibiotics
- Biofilm-Based Infections
- Biofilm-Specific Antibiotic Resistance
- Catheter related blood stream infection
- Foreign-body and implant infections
- Catheter related urinary tract infection
- Innovative approaches for the prevention of device-related infections
- Antiseptic-Coated Catheters
Track 9: Emerging infectious diseases
An emerging infectious disease (EID) is an infectious disease whose incidence has increased in the past 20 years and could increase in the near future. some of the infectious diseases which can be commonly seen in the hospitals are Norovirus, Mycobacterium abscessus, Klebsiella, Influenza , Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus, Vancomycin-resistant Enterococci, Tuberculosis, Vancomycin-intermediate or Vancomycin-resistant Staphylococcus aureus, Staphylococcus aureus.
- Bacterial infections: Gram-negative
- Bacterial infections: Gram-positive
- Viral infections
- Fungal infections
- Zoonotic infections
- Malarial drug resistance
- Influenza A (H1N1) virus
- Multidrug resistant tuberculosis
Track 10: Vaccines and Immunization
Immunization is a highly effective public health measure that reduces the incidence of infectious diseases, yet there has been relatively little effort toward the development of vaccines for nosocomial infections. Many nosocomial infections originate on mucosal surfaces (e.g., respiratory or gastrointestinal mucosa). As patients who are hospitalized once are more likely to be hospitalized again, a prime-boost immunization strategy, whereby a priming dose of vaccine for a nosocomial infection is administered mucosally.
- Innovations in development of vaccines
- Current clinical practices on vaccination
- Immunization of health-care workers
- Role of vaccination in healthcare systems
- Immune enhancement and genetic studies
- Criteria for vaccination and immunization schedule
- Recommendations of vaccines in immunocompromised patients
- Current clinical practices on vaccination
Track 11: Antimicrobial/ Antibiotic/ Antibacterial Resistance
Antimicrobial/ Antibiotic/ Antibiotic resistance is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases. Antibiotic resistance occurs when an antibiotic has lost its ability to effectively control or kill bacterial growth; in other words, the bacteria are "resistant" and continue to multiply in the presence of therapeutic levels of an antibiotic.
- Infections and resistance mechanisms of pathogens
- Surveillance of antimicrobial use and resistance
- Emerging issues in antibiotic resistance
- Prevalence of Multidrug-Resistant Organisms
- Genetic and physiological adaptation to the host
- Evolving microbes and resistant infections
- Immunology of Infectious Diseases
- Methicillin-resistant Staphylococcus aureus (MRSA)
Track 12: Antibiotics and Antimicrobial Use:
Antibiotics are used to treat or prevent some types of bacterial infection. They work by killing bacteria or preventing them from reproducing and spreading. They are often unnecessarily prescribed for viral infections, against which they have no effect. Not only antibiotics, other antivirals and antimicrobials are losing their effectiveness due to their irrational use and causing antimicrobial resistance.
- Novel antibiotics, spectrum of activity and their applications
- Antimicrobial Stewardship
- Antibiotic use and its relation to the emergence of resistant bacteria
- Pharmacokinetics and pharmacodynamics
- Antibiotic Heterogeneity and Antibiotic Cycling
- Monoclonal antibody as an anti-infective
- Antibiotic susceptibility testing
- Optimizing antibiotic usage in hospitals
Track 13: Occupational Health hazards and safety
Biological agents, including microorganisms and toxins produced by living organisms, can cause health problems in workers. Influenza is an example of a biohazard which affects a broad population of workers. Occupational illness results from exposure in a workplace to a physical, chemical or biological agent to the extent that the normal physiological mechanisms are affected and the health of the worker is impaired.
- Identifying and handling biological agent threats
- Occupational health hazards and illnesses
- Microbiology of the built environment
- Domestic and Indoor Microbiology
- Contamination and cross contamination on hospital surfaces and medical equipment
Track 14: Pharmaceutical Microbiology
Pharmaceutical Microbiology is an applied branch of Microbiology. It involves the study of microorganisms associated with the manufacture of pharmaceuticals. pharmaceutical microbiology include the research and development of anti-infective agents, the use of microorganisms to detect mutagenic and carcinogenic activity in prospective drugs, and the use of microorganisms in the manufacture of pharmaceutical products.
- Microbial and Biochemical Technology
- Antimicrobial Effectiveness Testing
- Bacterial Endotoxin Testing
- Microbial Examination of Non-Sterile Products
- Microbes and Environmental Management
- Strategies to prevent microbial contamination
- Sterile Pharmaceutical Manufacturing
- Wastewater treatment and bio solids reuse
Track 15: Therapeutic Approaches
Nosocomial infections are a major challenge for patient safety. Empirical antibiotic therapy should be based on thorough clinical evaluation and local epidemiological data on potential pathogens and susceptibility to antibiotics. The chosen therapy must be effective, limit the toxicity and be the narrowest spectrum possible. The choice of parenteral, oral or topical antibiotic formulations is made on the basis of clinical presentation (site and severity of infection).
- Evidence-Based Medicine
- Advances in treatment of persistent nosocomial infections
- Current and Future Treatment of Nosocomial Infections
- Critical Care
- Medical Care
- Surgical Care
- Wound Care
- Monoclonal Antibody as an Anti-Infective
- Research on antibiotic treatment and antibiotic de-escalation
- Modification of Empiric Antibiotic Regimens
- Appropriate Antibiotic Selection and Adequate Dosing
- Novel Therapeutic Strategies
Track 16: Pulmonary infection
Pulmonary infections are common and are caused by a wide range of organisms. Micro-organisms responsible may enter the lung by three potential routes:
via the tracheobronchial tree : most commonly due to inhalation of droplets of secretions from another infected human
environmental exposure e.g. fungal spores
via the pulmonary vasculature
direct injection e.g. intravenous drug use
secondary seeding from distant infection e.g. infective bacterial endocarditis
via direct spread from infection in the mediastinum, chest wall, or upper abdomen
- lobar pneumonia
- lobular pneumonia (or bronchopneumonia)
- pulmonary abscess
- interstitial pneumonia
Track 17: Pulmonary infection
Pediatric infections recurring or persistent disease caused by an infectious agent such as bacteria, a fungus, a parasite, or other rare infection, a pediatric infectious diseases
- Hospital infection control and epidemiology (identifying risk factors for disease and targets for preventive medicine and public policies
- Antibiotic resistance and how the body affects the drugs
Track 18 : Role of Nursing in Healthcare
The role of nurses has always been crucial in healthcare. Nurses are on the front line every day, tending to the sick, counseling patients on their health, and improving processes throughout the healthcare system. Now, nursing is expanding into healthcare redesign and management.
• Pediatric Nursing
• Surgical Nursing
• Cardiovascular Nursing
Past Conference Report
Market Analysis Report
Nosocomial infections or hospital acquired bacterial infections are type of infections commonly caused by bacterial pathogens and are acquired in healthcare facilities or hospitals. These pathogens should be examined in all patients who have developed some kind of clinical deterioration unexplained during the initial diagnosis. Currently, HAI market is a lucrative market venture due to increasing incidence rate of hospital acquired infections, which makes this industry a highly profitable and attractive market.
The following are the types of hospital acquired bacterial infections:
- Urinary Tract Infections (UTI)
- Blood Stream Infections (BSI)
- Surgical Site Infections
2nd International Congress on Nosocomial and Healthcare Associated Infections is an exciting opportunity for Healthcare professionals, doctors, students and pharmaceutical industries to showcase the new technology treatment in ICUs, the new products of your company, and/or the service your industry may offer to a broad international audience.
Global Market Research Report
The Global Nosocomial Infection Control Market is projected to reach USD 53.78 billion by 2021 and is growing at a CAGR of 8.3% during the forecast period from 2017 to 2021. Hospital acquired infections are also called as nosocomial infections and are acquired in hospitals and other healthcare facilities. These infections can occur up to 48 hours after hospital admission or up to 3 days after discharge or up to 30 days after an operation or in a healthcare facility, when the patient was admitted for reasons other than infection.
In the geographical analysis, North America is the leading market for hospital acquired bacterial infections treatment and testing market. Due to stringent hospital regulatory policies and increased government initiatives to prevent and control various hospital-acquired infections, this region is able to maintain its dominant position across the world. Europe closely follows North America is terms of growth, due to increasing incidence of hospital-acquired infections. According to the Health Protection Agency (HPA) approximately of patients in hospitals in England acquire some form of bacterial infection during their hospital stay. However, other regions such as South East Asia, Middle East and Latin America are expected to be the promising markets in the near future. Owing to the rising disposable income among population, increasing incidence of bacterial infections and developing healthcare infrastructure, these regions are expected to be the potential market in the near future.
Past Conference Report
Clinical Microbiology: Open Access
Journal of Infectious Diseases & Therapy: Open Access
Journal of Medical Microbiology & Diagnosis Open Access
All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.
Abstracts will be provided with Digital Object Identifier by